BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
BC Extra | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

ChemoCentryx became the latest biotech to post a triple-digit percentage gain based on a clinical readout, adding more than $1.3 billion in market cap after its avacopan showed statistical superiority to standard-of-care therapy in a...
BC Extra | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BC Extra | Sep 23, 2019
Financial News

Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

Innate proposes U.S. listing  Innate Pharma S.A. (Euronext:IPH) filed to raise up to $100 million total across a NASDAQ listing and a European private placement. The antibody company markets CD22-targeted immunotoxin Lumoxiti moxetumomab in the...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; lymphoma; solid tumors Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The trifunctional NK cell engagers...
BC Extra | Jun 13, 2019
Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

Hansoh gets $10B-plus valuation via Hong Kong IPO  Hansoh Pharmaceutical Group Co. Ltd. (HKSE:03692) priced its Hong Kong IPO Thursday, raising HK$7.9 billion ($1 billion) through the sale of 551.3 million shares at HK$14.26. The...
Items per page:
1 - 10 of 196
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
BC Extra | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

ChemoCentryx became the latest biotech to post a triple-digit percentage gain based on a clinical readout, adding more than $1.3 billion in market cap after its avacopan showed statistical superiority to standard-of-care therapy in a...
BC Extra | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BC Extra | Sep 23, 2019
Financial News

Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

Innate proposes U.S. listing  Innate Pharma S.A. (Euronext:IPH) filed to raise up to $100 million total across a NASDAQ listing and a European private placement. The antibody company markets CD22-targeted immunotoxin Lumoxiti moxetumomab in the...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; lymphoma; solid tumors Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The trifunctional NK cell engagers...
BC Extra | Jun 13, 2019
Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

Hansoh gets $10B-plus valuation via Hong Kong IPO  Hansoh Pharmaceutical Group Co. Ltd. (HKSE:03692) priced its Hong Kong IPO Thursday, raising HK$7.9 billion ($1 billion) through the sale of 551.3 million shares at HK$14.26. The...
Items per page:
1 - 10 of 196